青光眼或高眼压症药物治疗后选择性激光小梁成形术
该研究为LiGHT试验的事后探索性分析,评估药物治疗至少3年后行选择性激光小梁成形术(SLT)的结局。在320例初始接受降眼压滴眼液的患者中,112例(35.0%)接受SLT;换用SLT与用药数量减少相关(平均活性成分从1.38降至0.59,平均差0.79,95%CI 0.66至0.93,P<.001)。对于药物控制不佳眼,SLT可提供额外眼压控制,但未消除小梁切除术需求。
要点
- 药物换用SLT与用药数量减少相关,平均活性成分从1.38降至0.59(P<.001)。
- 换用SLT后72个月,60.5%眼无需药物或手术治疗。
- 升级至SLT平均眼压降低4.6 mm Hg(21.8%),62.5%眼达目标眼压且无需手术。
核心结论
- 该随机临床试验的二次分析发现,二次SLT与稳定药物控制眼的用药负担减少相关。
- 对于药物控制不佳眼,有证据表明SLT可提供额外眼压控制,但未消除小梁切除术需求。
研究设计与样本
- 该研究为多中心随机临床试验(LiGHT试验)的事后探索性分析,在英国国家健康服务系统内开展。
- 参与者为参与LiGHT试验的开角型青光眼或高眼压症患者,初始随机接受原发性SLT或原发性降眼压滴眼液并维持分配治疗路径3年。
- 使用滴眼液者随后允许接受二次SLT作为治疗转换(减少用药负荷)或治疗升级(需要更强治疗)。
- 共633例参与者进入LiGHT试验延长期,524例(82.8%)完成延长期(72个月)。
主要发现
- 320例接受原发性降眼压滴眼液者中,112例(35.0%)接受SLT:70例转换为SLT,29例以SLT作为治疗升级,13例一眼升级为SLT、另一眼转换为SLT。
- 转换为SLT与用药数量减少相关:平均(SD)活性成分从1.38(0.62)降至0.59(0.92),平均差0.79(95%CI 0.66至0.93)活性成分,P<.001。
- 72个月时,转换为SLT的69眼(60.5%)无需药物或手术治疗;转换前接受1种药物的62眼(83.8%)无需药物治疗。
- 升级至SLT与平均眼压降低4.6 mm Hg(21.8%)相关;72个月时30眼(62.5%)达到目标眼压且无需手术;9眼(18.7%)需要小梁切除术。
局限性
- 该研究为事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Primary selective laser trabeculoplasty (SLT) is a safe primary treatment for open-angle glaucoma (OAG) and ocular hypertension (OHT). However, there is limited evidence on its use as a secondary treatment, ie, after prior use of ocular hypotensive eye drops. OBJECTIVE: To evaluate outcomes following SLT after using hypotensive eye drops for at least 3 years. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc exploratory analysis of data from a multicenter randomized clinical trial conducted within the UK National Health Service. Participants were patients with OAG or OHT who participated in the LiGHT trial. Data were analyzed from February 2021 to December 2024. INTERVENTION: Participants were initially randomized to either primary SLT or primary hypotensive eye drops and remained on the allocated treatment pathway for 3 years. Participants using eye drops were then allowed to have secondary SLT as a treatment switch (to reduce their medication load) or as a treatment escalation (if more intense treatment was needed). Participants were treated and monitored according to a predefined protocol. MAIN OUTCOMES AND MEASURES: The outcomes of interest were rates of incisional glaucoma surgery, medication use, and intraocular pressure. RESULTS: In total, 633 participants entered the extension of the LiGHT trial, and 524 participants (82.8%) completed the extension (72 months). Of 320 participants receiving primary hypotensive eye drops, 112 (35.0%) received SLT: 70 participants switched to SLT, 29 participants had SLT as a treatment escalation, and 13 participants had SLT as a treatment escalation in 1 eye and as a treatment switch in the other eye. Switching to SLT was associated with a reduction in the number of medications (mean [SD], 1.38 [0.62] to 0.59 [0.92] active ingredients; mean difference, 0.79 [95% CI 0.66 to 0.93] active ingredients; P < .001). At 72 months, 69 eyes that switched to SLT (60.5%) needed no medical or surgical treatment, and 62 eyes receiving 1 drug before switching (83.8%) needed no medical treatment. Escalating to SLT was associated with a mean intraocular pressure reduction of 4.6 mm Hg (21.8%), and 30 eyes (62.5%) reached target intraocular pressure at 72 months without the need for surgery; 9 eyes (18.7%) needed a trabeculectomy. CONCLUSIONS AND RELEVANCE: This secondary analysis of a randomized clinical trial found that secondary SLT was associated with a reduction in the medication load for stable, medically treated eyes. For medically uncontrolled eyes, there is evidence that SLT could provide additional intraocular pressure control, but the need for trabeculectomy was not eliminated. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN32038223.
引用
- Konstantakopoulou E, Gazzard G, Garway-Heath D, et al. Selective Laser Trabeculoplasty After Medical Treatment for Glaucoma or Ocular Hypertension. JAMA Ophthalmol. 2025. PMID: 39976961. doi:10.1001/jamaophthalmol.2024.6492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。